Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.03 | 2.23 | 2.92 | 2.00 | 1.72 | 0.53 | 0.57 | 0.75 | 1.34 | 1.85 | 3.79 | 4.27 | 4.16 | 2.90 | 3.20 | 2.61 | 0.22 | 0.32 | 0.55 | 0.91 | 2.70 |
| — | +323.6% | +415.6% | +167.2% | +28.0% | -71.6% | -85.1% | -82.5% | -67.8% | -36.2% | +18.6% | +63.9% | +1793.3% | +802.9% | +480.7% | +186.1% | -91.9% | -84.7% | -78.4% | -65.7% | +25.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -127.0% | -32.5% | -40.4% | -33.3% | -28.2% | -30.1% | -26.2% | -20.0% | -16.4% | -13.1% | -10.9% | -10.5% | -9.8% | -10.9% | -16.2% | -16.5% | -12.6% | -12.8% | -11.5% | -11.8% | -10.6% |
| — | -8.1% | -54.0% | -67.0% | -72.2% | -129.5% | -139.9% | -89.7% | -66.9% | -20.2% | +32.3% | +36.2% | +22.1% | +14.6% | -40.3% | -39.2% | -18.8% | -17.3% | -26.4% | -44.4% | -53.0% | |
| ROA | -95.9% | -25.2% | -27.8% | -23.6% | -21.7% | -23.2% | -20.5% | -16.7% | -14.5% | -12.1% | -10.1% | -9.8% | -9.2% | -10.1% | -14.4% | -15.0% | -11.8% | -12.0% | -10.8% | -11.2% | -10.1% |
| — | -8.8% | -35.4% | -41.2% | -49.2% | -92.1% | -102.5% | -71.0% | -58.0% | -19.9% | +29.5% | +35.0% | +22.1% | +16.0% | -33.3% | -34.8% | -17.2% | -15.1% | -23.4% | -41.7% | -49.8% | |
| ROIC | -429.6% | -320.8% | -95.9% | -39.6% | -42.9% | -90.3% | -247.7% | -222.0% | -105.1% | -54.8% | -41.0% | -35.5% | -28.0% | -45.2% | -83.3% | -46.3% | -24.2% | -20.5% | -45.5% | — | -9177.0% |
| — | -255.3% | +61.3% | +82.1% | +59.2% | -64.8% | -504.3% | -524.5% | -275.2% | -21.2% | +50.8% | +23.3% | -15.9% | -120.4% | -83.3% | — | +99.7% | +90.3% | +55.8% | — | -15430.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.12 | 0.26 | 0.24 | 0.18 | 0.14 | 0.24 | 0.10 | 0.09 | 0.04 | 0.04 | 0.02 | 0.03 | 0.02 | 0.05 | 0.05 | — | — | — | — | — |
| — | -12.5% | +8.1% | +136.2% | +111.6% | +276.0% | +542.9% | +382.0% | +229.3% | +53.9% | -27.7% | -56.8% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.77 | 5.79 | 2.95 | 2.77 | 3.60 | 4.78 | 3.96 | 6.15 | 8.11 | 11.52 | 12.66 | 15.29 | 15.65 | 20.94 | 10.29 | 11.47 | 15.20 | 15.22 | 16.07 | 14.86 | 20.07 |
| — | +21.2% | -25.6% | -55.0% | -55.6% | -58.6% | -68.7% | -59.7% | -48.2% | -45.0% | +23.0% | +33.3% | +3.0% | +37.5% | -36.0% | -22.8% | -24.2% | -18.8% | -39.7% | -32.2% | -28.2% | |
| Quick Ratio | 2.77 | 5.79 | 2.95 | 2.77 | 3.60 | 4.78 | 3.96 | 6.15 | 8.11 | 11.52 | 12.66 | 15.29 | 15.65 | 20.94 | 10.29 | 11.47 | 15.20 | 15.22 | 16.07 | 14.86 | 20.07 |
| — | +21.2% | -25.6% | -55.0% | -55.6% | -58.6% | -68.7% | -59.7% | -48.2% | -45.0% | +23.0% | +33.3% | +3.0% | +37.5% | -36.0% | -22.8% | -24.2% | -18.8% | -39.7% | -32.2% | -28.2% | |
| Interest Coverage | -82.76 | -97.68 | -67.42 | -74.53 | -75.83 | -78.03 | -121.26 | -31.76 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CABA stock.
Cabaletta Bio, Inc.'s current P/E is -1.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cabaletta Bio, Inc.'s business trajectory between earnings reports.